Get intelligentvalue.com

Own it today or select a payment plan

Buy Now$3,879Payment Plan$325/mo

Secured by Stripe

Premium Domain Name

intelligentvalue.com

is available for purchase

51 views

Visitors from

US 54%·

AU 32%·

IN 7%·

GB 2%·

FR 2%

Perfect for

Financial Consulting Technology Startups Educational Services Economic Forecasting E-commerce Solutions Business Analytics Artificial Intelligence Solutions Investment Advisory Strategic Planning Market Research

Unlock the potential of 'intelligentvalue.com', a premium domain that embodies sophistication and expertise in investment advisory and financial consulting. Perfect for businesses in artificial intelligence solutions, market research, and strategic planning, this memorable domain conveys a strong branding message that resonates with clients seeking innovative and data-driven insights. Elevate your presence in the competitive landscape with a digital identity that signifies intelligence, value, and forward-thinking solutions.

Safe & Secure

Protected transactions with Stripe

Fast Transfer

Domain transferred within 24 hours

Flexible Payments

Interest-free payment plans available

Cencora Earnings: What To Look For From COR

May 06, 2025 at 03:02 AM EDT

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

COR Cover Image

Healthcare distributor Cencora (NYSE: COR) will be reporting earnings tomorrow before the bell. Here’s what to expect.

Cencora beat analysts’ revenue expectations by 5.2% last quarter, reporting revenues of $81.49 billion, up 12.8% year on year. It was a very strong quarter for the company, with a narrow beat of analysts’ full-year EPS guidance estimates and a decent beat of analysts’ EPS estimates.

Is Cencora a buy or sell going into earnings? Read our full analysis here, it’s free.

This quarter, analysts are expecting Cencora’s revenue to grow 10.7% year on year to $75.7 billion, improving from the 7.8% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $4.10 per share.

Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Cencora has only missed Wall Street’s revenue estimates once over the last two years, exceeding top-line expectations by 3% on average.

Looking at Cencora’s peers in the health insurance providers segment, some have already reported their Q1 results, giving us a hint as to what we can expect. Alignment Healthcare delivered year-on-year revenue growth of 47.5%, beating analysts’ expectations by 4.4%, and CVS Health reported revenues up 7%, topping estimates by 1.5%. Alignment Healthcare traded down 7% following the results while CVS Health was up 1.2%.

Read our full analysis of Alignment Healthcare’s results here and CVS Health’s results here.

There has been positive sentiment among investors in the health insurance providers segment, with share prices up 4.4% on average over the last month. Cencora is up 6.3% during the same time and is heading into earnings with an average analyst price target of $297.49 (compared to the current share price of $291.97).

Today’s young investors won’t have read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next.

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article